Abstract bekijken

Deze abstract is toegekend aan sessies
TitelIs Olisense the new Holy Grail for corneal neovascularization after infectious keratitis?
DoelTo describe the clinical response of corneal neovascularization following Acanthamoeba keratitis in a patient treated with Olisense (Aganirsen, GS-101), a novel antisense mRNA eye drop with anti-angiogenic properties.
MethodesA patient with PCR-confirmed Acanthamoeba keratitis developed progressive corneal opacification and neovascularization despite intensive antimicrobial therapy. Once the infection was clinically quiescent and no antimicrobial treatment was needed, adjunctive therapy with Olisense was initiated.
ResultatenAfter one month of Olisense therapy, slit-lamp evaluation revealed decreased vascular congestion and regression of neovascularization, while the overall corneal opacification remained stable. The treatment was well tolerated and no adverse ocular effects were observed, supporting the safety profile reported in earlier trials.
ConclusieOlisense is an antisense oligonucleotide that selectively downregulates fibroblast growth factor receptor-1 expression, thereby inhibiting angiogenic signalling and thus corneal neovascularization. Previous studies have shown efficacy in herpetic and inflammatory keratitis with significant reduction of neovascular surface area. This case highlights its potential role in post-infectious keratitis, where regression of pathologic vascularization may improve long-term prognosis and graft survival after keratoplasty. Olisense represents a valuable adjunct to the management post-infectious corneal neovascularization.
BelangenverstrengelingNee
Auteurs 1
InitialenM
NaamLauwers
InstituutUZ Leuven
StadLeuven
Auteurs 2
InitialenH
NaamDelbeke
InstituutUZ Leuven
StadLeuven
top ^